Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort

Background Metabolic dysfunction‐associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N‐terminal propeptide of collagen type 3 (PRO‐C3) is a biomarker of advanced fibrosis in MAFLD and PRO‐C3 may be involved in renal fibrosis. We aimed to use PRO‐C3 mea...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2024-05, Vol.44 (5), p.1129-1141
Main Authors: Tang, Liang‐Jie, Sun, Dan‐Qin, Song, Sherlot Juan, Yip, Terry Cheuk‐Fung, Wong, Grace Lai‐Hung, Zhu, Pei‐Wu, Chen, Sui‐Dan, Karsdal, Morten, Leeming, Diana Julie, Jiang, Pei, Wang, Cong, Chen, Qiang, Byrne, Christopher D., Targher, Giovanni, Eslam, Mohammed, George, Jacob, Wong, Vincent Wai‐Sun, Zheng, Ming‐Hua
Format: Article
Language:English
Subjects:
Accuracy
Albumins
Algorithms
Asian
Biomarkers
Biopsy
chronic kidney disease
Collagen (type I)
Complement C3
Creatinine
Fatty liver
Fibrosis
Humans
Kidney diseases
Kidneys
Liver
Liver Cirrhosis
Liver diseases
liver fibrosis
metabolic dysfunction‐associated fatty liver disease
metabolic dysfunction‐associated steatotic liver disease
Non-alcoholic Fatty Liver Disease
N‐terminal propeptide of type 3 collagen
Predictions
Regression analysis
Renal Insufficiency, Chronic
Risk Factors
risk prediction
Serum
Statistical analysis
Subgroups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Metabolic dysfunction‐associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N‐terminal propeptide of collagen type 3 (PRO‐C3) is a biomarker of advanced fibrosis in MAFLD and PRO‐C3 may be involved in renal fibrosis. We aimed to use PRO‐C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease (MAFLD–CKD). Methods A derivation and independent validation cohort of 750 and 129 Asian patients with biopsy‐confirmed MAFLD were included. Serum PRO‐C3 concentration was measured and regression analyses were performed to examine associations with MAFLD–CKD. A derivative algorithm for MAFLD–CKD risk prediction was evaluated with receiver operator characteristic (ROC) curve analysis. Results The study included two Asian cohorts (n = 180 with MAFLD–CKD; mean‐eGFR: 94.93 mL/min/1.73 m2; median‐urinary albumin‐to‐creatinine ratio: 6.58 mg/mmol). PRO‐C3 was associated with the severity of MAFLD‐CKD and independently associated with MAFLD–CKD (adjusted odds ratio = 1.16, 95% confidence interval [CI]: 1.08–1.23, p 
ISSN:1478-3223
1478-3231
1478-3231
DOI:10.1111/liv.15878